Portal de Periódicos da CAPES

Relevant SARS‐CoV‐2 viremia is associated with COVID‐19 severity: Prospective cohort study and validation cohort

2022; Wiley; Volume: 94; Issue: 11 Linguagem: Inglês

10.1002/jmv.27989

1096-9071

Laura Cardeñoso, Emilia Roy‐Vallejo, Nelly Daniela Zurita Cruz, Marta Chicot Llano, Elena Ávalos, Ana Barrios, Julia Hernando Santos, Javier Ortíz, Sebastián C. Rodríguez García, Alexandra Martín Ramírez, Marianela Ciudad Sañudo, Celeste Marcos, Elena García Castillo, Leticia Fontán García–Rodrigo, Begoña González, Rosa Méndez, Isabel Iturrate, Ancor Sanz‐García, Almudena Villa, Ana Sánchez Azofra, Begoña Quicios, David San Segundo Arribas, Jesús Álvarez Rodríguez, Pablo Javier Patiño Grajales, Marina Trigueros, Miren Uriarte, Ana Triguero Martínez, Cristina Arévalo, José María Galván‐Román, Rosario García‐Vicuña, Julio Ancochea, Joan B. Soriano, Alfonso Canabal Berlanga, Cecilia Muñoz Calleja, Rafael de la Cámara, Carmen Busca, Isidoro González‐Álvaro, Diego Aníbal Rodríguez-Serrano,

SARS-CoV-2 and COVID-19 Research

Abstract Early kinetics of SARS‐CoV‐2 viral load (VL) in plasma determined by quantitative reverse‐transcription polymerase chain reaction (RT‐PCR) was evaluated as a predictor of poor clinical outcome in a prospective study and assessed in a retrospective validation cohort. Prospective observational single‐center study including consecutive adult patients hospitalized with COVID‐19 between November 2020 and January 2021. Serial plasma samples were obtained until discharge. Quantitative RT‐PCR was performed to assess SARS‐CoV‐2 VL. The main outcomes were in‐hospital mortality, admission to the Intensive Care Unit (ICU), and their combination (Poor Outcome). Relevant viremia (RV), established in the prospective study, was assessed in a retrospective cohort including hospitalized COVID‐19 patients from April 2021 to May 2022, in which plasma samples were collected according to clinical criteria. Prospective cohort: 57 patients were included. RV was defined as at least a twofold increase in VL within ≤2 days or a VL > 300 copies/ml, in the first week. Patients with RV ( N = 14; 24.6%) were more likely to die than those without RV (35.7% vs. 0%), needed ICU admission (57% vs. 0%) or had Poor Outcome (71.4% vs. 0%), ( p < 0.001 for the three variables). Retrospective cohort: 326 patients were included, 18.7% presented RV. Patients with RV compared with patients without RV had higher rates of ICU‐admission (odds ratio [OR]: 5.6 [95% confidence interval [CI]: 2.1–15.1); p = 0.001), mortality (OR: 13.5 [95% CI: 6.3–28.7]; p < 0.0001) and Poor Outcome (OR: 11.2 [95% CI: 5.8–22]; p < 0.0001). Relevant SARS‐CoV‐2 viremia in the first week of hospitalization was associated with higher in‐hospital mortality, ICU admission, and Poor Outcome. Findings observed in the prospective cohort were confirmed in a larger validation cohort.